Bitcoin price today: slips below $113k, near 6-wk low despite Fed cut bets
MOUNTAIN VIEW, Calif. - Aditxt, Inc. (NASDAQ:ADTX), a micro-cap biotech company with a market capitalization of $2.61 million, announced Monday its new "bitXbio" capitalization strategy that combines Bitcoin reserves with an equity line facility to support its biotech commercialization efforts ahead of planned monetization events beginning in 2026.
The company’s board recently approved the Bitcoin-backed treasury initiative, which aims to strengthen Aditxt’s balance sheet while aligning its enterprise value with future commercialization opportunities. The plan includes establishing a Bitcoin reserve, subject to available funding, alongside strategic deployment of capital from its existing equity line facility. According to InvestingPro data, the company faces significant liquidity challenges with a current ratio of 0.08, indicating its short-term obligations exceed its liquid assets.
"BitXbio is a forward-looking strategy designed to align our capital structure with the value-creation potential of our biotech pipeline," said Amro Albanna, Co-founder and CEO of Aditxt, according to the press release.
Aditxt currently has approximately $125 million available under its common stock purchase agreement with its equity line investor. The company can presently sell up to 50 million shares of common stock through its registration statement that became effective on June 30.
As part of its 2026 monetization strategy, Aditxt is positioning its Pearsanta subsidiary for an initial public offering. The company operates as a social innovation platform with programs focused on autoimmunity and early disease detection. Despite challenging market conditions, with the stock down 97.46% over the past six months, analysts project revenue growth of 43.78% for fiscal year 2025. InvestingPro subscribers have access to 12 additional key insights about Aditxt’s financial health and growth prospects.
Aditxt is also working toward closing its proposed acquisition of Evofem in the second half of 2025, which would add a women’s health program to its portfolio. The transaction remains subject to several conditions, including Evofem shareholder approval and Aditxt raising approximately $17 million to meet closing obligations.
The company stated in its announcement that the bitXbio plan reflects its broader vision to build a global biotech platform capable of commercializing innovations through digital capitalization.
In other recent news, Aditxt, Inc. announced the appointment of Saundra Pelletier, CEO of Evofem Biosciences, to its Board of Directors, signaling a strategic push into the women’s health sector. The company is also working towards acquiring Evofem, with the merger expected to close in the latter half of 2025, pending shareholder approval and the raising of approximately $17 million. In financial developments, Aditxt secured a $233,000 unsecured loan from its CEO, Amro Albanna, with a 7.5% annual interest rate. Additionally, the company raised $256,250 through the private sale of senior notes, which carry a 10% interest rate and mature in May 2025. Aditxt has also made a $1.5 million investment in Evofem, acquiring a convertible note and a warrant to purchase shares, as part of its merger strategy. The company recently regained compliance with Nasdaq’s listing standards, a significant step in maintaining its exchange standing. Aditxt’s agreements with Appili Therapeutics and Evofem Biosciences require raising about $34 million to meet financial obligations, including payments to Evofem’s noteholder. These developments reflect Aditxt’s ongoing efforts to strengthen its financial position and advance its strategic initiatives.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.